Navigation Links
Novocure Presents Preclinical Data at the American Association for Cancer Research (AACR)
Date:4/10/2013

WASHINGTON, April 10, 2013 /PRNewswire/ -- Novocure announced today that new data from preclinical testing of NovoTTF Therapy in non-small cell lung carcinoma (NSCLC), ovarian and pancreatic cancer has been presented at the 2013 AACR Annual Meeting.  The new data builds on existing published research describing the potential efficacy of NovoTTF Therapy in a wide range of solid tumors.

"The results presented at the AACR Annual Meeting demonstrate that NovoTTF Therapy inhibits the growth of squamous histology non-small cell lung cancer as well as pancreatic and ovarian cancers in preclinical models," said Eilon Kirson , M.D., Ph.D., Novocure's Chief Science Officer and Head of Research and Development.  "We intend to build on this research through clinical trials evaluating the efficacy of NovoTTF Therapy in these indications when delivered in combination with chemotherapy."

AACR Annual Meeting 2013 Abstracts

  • Giladi et al, Development of an orthotopic squamous cell carcinoma (SCC) lung cancer model.  Data were presented describing a new in vivo model to test the efficacy of anti-neoplastic treatments in SCC lung cancer.  Abstract #340.
  • Giladi et al, NovoTTF Therapy inhibited the growth of pancreatic and ovarian cancer in vitro. Additionally, the data supports a conclusion that modulation of NovoTTF Therapy frequency may overcome treatment resistance. Abstract #5569.

About NovoTTF Therapy
NovoTTF Therapy is delivered by portable, non-invasive medical devices designed for continuous use throughout the day by the patient. NovoTTF Therapy has been shown in in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The delivery systems weigh about six pounds and create a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division. The NovoTTF-100A System is not approved in the US for any indications except for recurrent glioblastoma brain tumors. The safety and effectiveness of NovoTTF Therapy in lung, pancreas and ovarian cancers has not been established.

About Novocure™
Novocure Limited is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors. Novocure's US operations are based in New York, NY and Portsmouth, NH and the company's research center is located in Haifa, Israel. For additional information about the company, please visit www.novocure.com.

Contact:
Frank Leonard
(212) 767-7536
media@novocure.com  


'/>"/>
SOURCE Novocure
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novocure™ to Present NovoTTF™ Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology
2. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
3. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
4. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
5. Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
6. Cardium Presents Year-End 2012 Financial Results And Recent Developments
7. Pharmagen Presents to North Carolina General Assembly at N.C. Bios Legislative Breakfast
8. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
9. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
10. Versus Presents New Hand-Hygiene Alliance, Wireless Sensors and RTLS Education at HIMSS13
11. University Hospitals Case Medical Center Presents Study On The Elimination Of Retained Surgical Sponges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund ... (NCADD) is recommending the film Whispering Spirits and its discussion guide for ... as an education tool in the war against teen drug abuse. NCADD is ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... MA (PRWEB) , ... December 08, 2016 , ... ... Workers Compensation Research Institute (WCRI) officially opened registration today for its 33rd ... Hotel in Boston, MA . , The theme of the conference is “Persistent ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the ... advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, ... Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up with ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... 10.2 version gives development continuity to its innovative Unified Instance Manager architecture, ... capacity. In addition, this new version optimizes the unattended auto-dialing system without ...
Breaking Medicine News(10 mins):